We refuse to give up. Ever.

In laboratories and neighborhoods in 30 countries, Susan G. Komen works every day for the moment that we can say, “No one will die of breast cancer.”

Ending breast cancer was our founder’s promise to her sister.

Today, it is our Promise to all women and men.
In 2015, I participated in a Susan G. Komen symposium with some of the world’s brightest minds in oncology, technology, health, and patient advocacy. We were looking for ways to harness untold amounts of data from patient records and research – on a global scale – specifically for the benefit of people with breast cancer. This Susan G. Komen Big Data for Breast Cancer Summit (#BD4BC), in collaboration with the Robertson Foundation at the prestigious Rockefeller University in New York, was the first and, so far, the only effort of any breast cancer organization to explore Big Data specifically for breast cancer.

Exploration into Big Data for breast cancer is a complex and seemingly impossible challenge. In other words, it’s right up Komen’s alley.

Also this year, I witnessed the convening of the best and the brightest of our community leaders, scientists, Komen Affiliates, and even an Olympic athlete, to take on yet another huge and complex issue in breast cancer: the appalling and unfair difference in breast cancer outcomes for African-American women in our country. African-American women are about 40 percent more likely to die of breast cancer in the U.S. and in some cities, death rates are three times higher. In our view, this constitutes a public health crisis that must be addressed.

Supported by a commitment from the Fund II Foundation, Komen is taking a unique approach by convening community leaders in 10 of the nation’s hardest-hit metropolitan areas. Together, we explored the unique medical, genetic, socioeconomic, cultural and psychosocial issues affecting breast cancer outcomes locally. And we are building programs to reduce breast cancer deaths in African-American women in those cities, led by the civic, health, religious and community leaders who know their regions best.

Building health equity programs city-by-city is another complex challenge. Seemingly impossible. Also right up Komen’s alley.

These examples from just the past year underscore what I have witnessed in my more than 30 years as a board member and volunteer with Susan G. Komen: our unique ability to not only take on, but take on a leadership role in addressing the most complex and difficult challenges in breast cancer.

To our Komen Partners, Donors, Affiliates, Staff and Friends:

In 2015, I participated in a Susan G. Komen symposium with some of the world’s brightest minds in oncology, technology, health, and patient advocacy. We were looking for ways to harness untold amounts of data from patient records and research – on a global scale – specifically for the benefit of people with breast cancer. This Susan G. Komen Big Data for Breast Cancer Summit (#BD4BC), in collaboration with the Robertson Foundation at the prestigious Rockefeller University in New York, was the first and, so far, the only effort of any breast cancer organization to explore Big Data specifically for breast cancer.

Exploration into Big Data for breast cancer is a complex and seemingly impossible challenge. In other words, it’s right up Komen’s alley.

Also this year, I witnessed the convening of the best and the brightest of our community leaders, scientists, Komen Affiliates, and even an Olympic athlete, to take on yet another huge and complex issue in breast cancer: the appalling and unfair difference in breast cancer outcomes for African-American women in our country. African-American women are about 40 percent more likely to die of breast cancer in the U.S. and in some cities, death rates are three times higher. In our view, this constitutes a public health crisis that must be addressed.

Supported by a commitment from the Fund II Foundation, Komen is taking a unique approach by convening community leaders in 10 of the nation’s hardest-hit metropolitan areas. Together, we explored the unique medical, genetic, socioeconomic, cultural and psychosocial issues affecting breast cancer outcomes locally. And we are building programs to reduce breast cancer deaths in African-American women in those cities, led by the civic, health, religious and community leaders who know their regions best.

Building health equity programs city-by-city is another complex challenge. Seemingly impossible. Also right up Komen’s alley.

These examples from just the past year underscore what I have witnessed in my more than 30 years as a board member and volunteer with Susan G. Komen: our unique ability to not only take on, but take on a leadership role in addressing the most complex and difficult challenges in breast cancer.

The work left to be done is more complex and involved than we might have imagined three decades ago.

It began with our founder Nancy Brinker’s promise to her dying sister, Suzy, to end breast cancer forever. Since then, Komen has always stared the impossible in the eye and put what is possible in its place, building a movement that has helped to reduce breast cancer death rates by 37 percent in the U.S. since 1990, while funding the research and programs that have improved both the quality – and quantity – of life for millions facing this disease.

Yet we are far from done when more than 40,000 U.S. women and men are still dying of breast cancer annually, and when so many face barriers to quality treatment and support that could save them.

We will continue to fund the research that will one day lead to cures (at $920 million, our investment is the largest, still, of any nonprofit outside the federal government), with a focus on aggressive and metastatic breast cancers that claim so many lives.

We also will redouble our efforts to ensure that all people have access to high-quality, timely breast cancer care, wherever they live. We work in thousands of communities in 30 countries to provide the financial, medical and psychosocial support that so many people need. Our help can be as straightforward as funding a local ride-to-treatment program, or as complicated as helping to build health equity programs one community at a time.

Going forward, we are energized by the recent additions of board members and executive leaders who are breathing new vitality and purpose into our organization. Together, we are feeling renewed focus and confidence in the potential of our organization and our movement to achieve a world without breast cancer.

Nancy’s promise to Suzy has become our promise to all women and men, and we are closer to fulfilling that promise today than at any time in our history.

In the pages that follow, you will see how Susan G. Komen is once again leading the way.

On behalf of the Komen Board of Directors, thank you to our partners, donors, Affiliates, staff and volunteers who make Susan G. Komen’s work possible. We have never, and could never, achieve our mission without the support, friendship and hard work of all of you. Thank you for your confidence and determination to help us build a world where no woman or man suffers breast cancer, ever again.

Linda P. Custard
Board Chair 2013-2016
Research

For every victory against breast cancer, challenges remain. Even as breast cancer death rates decline in the U.S., metastatic breast cancers still claim more than 40,000 lives each year. Even as millions of women and men benefit today from promising new treatments and technology, people die because they don’t have access to quality cancer care.

This is why Susan G. Komen has always taken a two-fold approach to ending the disease: taking the breast cancer fight to the laboratories — and to the streets.

Our research program is large and comprehensive.

We seek answers.

We seek cures.

We are focused on the breast cancers that kill.

In FY16, nearly 40 percent of our research grants focused on metastatic breast cancer, including funding for:

- Dr. Abhishek Sharma’s (University of Illinois at Urbana-Champaign) work to develop a new drug for women whose aggressive ER+ form of breast cancer has become resistant to standard treatment.
- Dr. April Kloxin’s (University of Delaware) research to understand the triggers that “wake up” breast cancer cells that have lain dormant for long periods and caused them to spread to other organs.
- Dr. Priscilla Brastianos, who raced to save her mother’s life from breast cancer that had spread, or metastasized, to the brain. Too late to save her mother, she works today on brain metastasis in hopes of saving others.
- Komen grantee Dr. Abenaa Brewster’s search for clues in blood, tumors and tissue to unlock the mysteries of how an aggressive form of breast cancer – triple negative breast cancer – develops.

A commitment to cutting-edge research means boldly embracing new tools and approaches never used before. Like social media.

- In October 2015, Komen grantee Dr. Nikhil Wagle launched a project that tried something that had never been tried before in medical research: going straight to metastatic breast cancer patients through social media. The MBC Project allowed patients to opt in and share their tissue and medical records to accelerate research.
- Shortly thereafter, Komen awarded Dr. Wagle $375,000 to analyze the data that had been collected; specifically, to investigate MBC in young women. The MBC Project continues, growing its sample repository, opening up new research possibilities, and showing us that where there is passion, there is innovation.
- Komen is also the first and only breast cancer organization to explore the potential of Big Data specifically for breast cancer research and patient care, bringing together technology, health, government and civic leaders to a consortium on Big Data for Breast Cancer (#BD4BC) in 2015. From that conference, we are building collaborations and partnerships to bring the benefits of Big Data to our effort to end breast cancer.
- We identified a funding crisis for early-career breast cancer researchers, who were leaving the field because of a lack of research dollars from the federal government. In FY16, Komen funded more than $16 million to these young researchers, while continuing to fund established scientists.
The Power of (More Than) One

Strategic Programs and Partnerships
As large, knowledgeable and forward-thinking as Komen is, we understand that no one organization or person can or will cure breast cancer. Our expertise and breadth provides a unique platform to lead collaboration in a mutual mission to end breast cancer. In FY16 alone:

- Komen continued to work through the groundbreaking Metastatic Breast Cancer Alliance, a consortium of 40 nonprofit organizations and companies focused on research and support for people living with metastatic breast cancer.
- We began building a network of community and health leaders in 10 cities to develop local programs focused on breast cancer in African-American women, who are about 40 percent more likely to die of breast cancer than their white counterparts.

In FY16, we partnered with many organizations to further our mission, including:

Working together, across organizations and disciplines, we can create an even greater impact than any one person or organization.
Health Equity

A woman in Nebraska may have to travel two hours – if she has a car – to get a mammogram. A minimum-wage worker in New York City may not have money for the substantial co-pay required for surgery and medications. A woman in Texas can’t miss work and doesn’t want to worry her family, so she ignores the lump in her breast until the pain forces her to the emergency room for care.

Breast cancer does not kill by biology alone. In fact, some scientists estimate that as many as 30 percent of breast cancer deaths could be avoided if everyone had access to — and received — timely, high-quality breast care. This is why Komen has made a commitment to achieving health equity for all. We are uniquely qualified to do so.

Where you live should not determine whether you live.

Individuals who live in rural or remote areas often face barriers to receiving timely and sufficient health care. This can be due to geographic isolation, low socioeconomic status, and lack of health insurance.

In FY16, Komen funded 222 community grants targeting individuals living in rural areas, seeking to improve access to breast health and breast cancer treatment services by providing multiple services, including transportation, free or low-cost services and patient navigation.

“A member of our community had to travel 1 ½ hours each way for daily treatment. There were young children at home, but her husband had to be with her during the treatment. A Komen grantee, CARTI, provided housing for the patient and the spouse two or three days a week, and they drove to treatment the other days, in an effort to make the situation as normal as possible for the children.”

— Komen Arkansas

Our Unique Approach

- Komen is the only breast cancer organization with a network of Affiliates that fund programs to pay co-pays, help eliminate transportation barriers to care, provide medical supplies and medications, and fund patient navigators who can intervene and guide women and men through a complex and challenging health-care system. Our Affiliates are also a vital source of education for their communities on breast health needs, and work in collaboration with others to close the gaps in breast care in their communities.

- Our local approach means that we can identify — and help to resolve — issues unique to the neighborhoods we serve. We did so in FY16 with a $109.3 million investment in about 1,000 local programs ranging from bus vouchers to treatment to co-pays for surgeries.

- Our local presence is augmented by a global perspective that allows us to understand — and help to solve — the broader issues that contribute to breast cancer mortality.

- We began a series of African-American Breast Cancer Disparities Roundtables in the 10 metropolitan areas in the U.S. with the highest disparities in breast cancer outcomes. Each roundtable gathered 40 community leaders to collectively discuss barriers, opportunities, needs, priorities, and, above all, solutions to improve African-American breast cancer outcomes. This served as an important “first step” in our African-American Health Equity Initiative to empower communities and implement programmatic activities.

2015 Disparities Roundtables

<table>
<thead>
<tr>
<th>Location</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Washington, DC</td>
<td>March 2015</td>
</tr>
<tr>
<td>Oakland, CA</td>
<td>July 2015</td>
</tr>
<tr>
<td>Memphis, TN</td>
<td>August 2015</td>
</tr>
<tr>
<td>Chicago, IL</td>
<td>October 2015</td>
</tr>
<tr>
<td>St. Louis, MO</td>
<td>October 2015</td>
</tr>
<tr>
<td>Dallas, TX</td>
<td>November 2015</td>
</tr>
</tbody>
</table>


- We serve women across the spectrum of diversity: rural, urban, young, old, Latino, Asian/Pacific Islander, African-American, Caucasian, Native American, LGBTQ, and people with disabilities. Our goal is to help all women and men overcome the unique issues that serve as barriers to their care.

- To ensure that future generations benefit, we are encouraging students to make health disparities their life’s work, with more than $1.2 million in FY16 for three new Graduate Training Programs in Breast Cancer Disparities. These include inaugural programs at the University of Chicago, UNC at Chapel Hill, and North Carolina Central University.
Education and Support

- 18,000 people received financial, medical or other support last year from the Komen-funded National Treatment Assistance Fund, administered by Komen with our partners CancerCare and the Patient Advocate Foundation. Komen has granted more than $9 million to the Assistance Fund in the last 5 years.
- Our national Breast Care Helpline 1-877 GO KOMEN (1-877-465-6636) connected more than 14,000 women, men and families to breast health and breast cancer information, local support services and resources for help.
- Women and men turned to Komen’s comprehensive website komen.org more than 7 million times for information about breast cancer. The website guided women and men from risk reduction, detection and treatment, to survivorship issues. What do I ask my doctor? What does this diagnosis mean? What’s next? Komen’s website has the answers.
- In communities and workplaces, Komen distributed more than 2.6 million print educational materials to the general public, our corporate partners and Affiliates.

When people need help — or answers — Komen is there.

“Donna” was a 36-year-old single mother of a two-year-old. She was struggling financially when she was diagnosed with stage III breast cancer in 2015. A Komen grantee and partner — CancerCare — put Donna in touch with our Komen North Jersey Affiliate, which was able to help with her transportation costs, and enroll her in a local program that provided meals for her and her son while she was undergoing treatment. We’re always thrilled when we can help people when they need us most.”

— Komen North Jersey

*name has been changed to protect client confidentiality.*
Affiliate Programs

Research will help us achieve an end to breast cancer. In the meantime, tens of thousands of people need help before, during and after a breast cancer diagnosis today. Susan G. Komen is the only breast cancer organization with local networks that do just that. In FY16, our Affiliates:

- Funded 967 community grants for more than $42 million to pay for treatment, diagnostic, patient navigation, screening and education services.
- Funded 104 community grants for people living with metastatic — or stage IV — breast cancer. These grants helped pay for treatment, provided financial support, and connected metastatic patients with caregivers, health-care providers and researchers.
- Focused on populations with special issues and underserved communities, including:
  - 560 grants reaching African-Americans
  - 581 grants addressing Hispanics/Latinos
  - 28 grants for LGBTQ individuals, and
  - 222 grants targeting individuals living in rural areas
- Led cancer coalitions, educated state/federal legislators on breast health issues, conducted community needs assessments, and provided community breast health education.

Only Komen has a network of Affiliates working in thousands of communities to help people where they live.

“I asked the staff at the radiology center if I could wait and get the results that day. I don’t know if all of our (Native) women know that they can ask for that. The time waiting for the results is hard on all of us and our families. We, as Native women, care for so many others. We don’t want to be a burden on our family because we have cancer. Finding the result quickly was very important for me and my family.”

– Komen Puget Sound

Up to 75 percent of the funds raised in local communities stays in local communities to meet critical needs of women and men.

At least 25 percent raised in our communities supports Komen’s national breast cancer research program.
To achieve our mission, scientific progress must be complemented by sound legislative and regulatory policy.

Advocacy

Susan G. Komen fights on Capitol Hill and across the country to ensure that women and men have access to high-quality breast health and breast cancer care. Our efforts have helped increase federal research funds, and preserved programs serving the underserved. Our priorities are to:

- Support expanded federal funding for all biomedical research, especially breast cancer research at the National Institutes of Health (NIH) and the Department of Defense (DOD);
- Support state and federal funding for the National Breast and Cervical Cancer Early Detection Program (NBCCEDP);
- Advocate for policies to improve insurance coverage of breast cancer treatments (specifically, increased access to drug therapies and limiting out-of-pocket costs for diagnostic mammography); and
- Evaluate state and federal policies to increase awareness, education, and access to clinical trials for all patient populations.

Our FY16 Successes Include:

- Secured $2 billion increase for the National Institutes of Health in the FY16 Omnibus Appropriations Bill.
- Successfully advocated against an amendment that would have eliminated most of the DOD’s Congressionally Directed Medical Research Programs, including the Breast Cancer Research Program.
- Advocated at the federal and state levels to secure an additional $3 million in funding for the National Breast and Cervical Cancer Early Detection Program.
- Supported and advocated for the reauthorization of the Breast Cancer Research Stamp, which provides significant funds for breast cancer research. The bill reauthorized the research stamp for four more years.
- Engaged in federal and state coalitions to increase access to oral anticancer medications.
- Brought Affiliate representatives and advocates to Washington, D.C., for personal meetings with congressional offices, to press Komen’s legislative priorities.
Breast cancer knows no borders, and neither does Komen.

Global Partnerships

From Africa to Latin America, Susan G. Komen works in more than 30 countries to help stem a growing global cancer tsunami. Our focus is on low- and middle-income countries where knowledge and resources are scarce. We work in-country, with local experts, and through partnerships.

- In partnership with the All-China Women’s Federation, Komen launched the Pink Alliance to advance breast cancer awareness and education in China. Komen developed a toolkit for health educators in collaboration with other global partners: GEhealthymagination, The China Women’s Development Foundation and Pangaea Global AIDS.

- Through Komen’s five-year partnership with Pink Ribbon Red Ribbon (PRRR), which includes founding partner organizations such as the George W. Bush Institute, UNAIDS, and the U.S. Department of State. Merck and Komen are supporting the expansion of PRRR programs to Zambia and Tanzania, and a variety of activities to develop and scale up education, screening and treatment services for breast and cervical cancer. As a result of the Merck/Komen investment:
  - Two breast cancer clinics were established in Zambia that perform clinical breast examinations, evaluation of breast abnormalities, and ultrasound-guided breast biopsies.
  - Education programs have now reached at least 200 medical professionals through lectures and conferences.
  - Trainings of health-care professionals have helped increase access to core clinical services.

- Susan G. Komen engaged a Mexican network of organizations from multiple sectors to discuss specific areas of need related to metastatic breast cancer in Mexico. The initiative was supported by Pfizer.
Komen envisions a world in which health care is a seamless web of information.

Big Data/BD4BC

- Komen envisions a world where patients are informed about their data and are empowered to share it and participate in their health care; data systems are linked and easily accessible; genomics (and other -omics) are universally available and user-friendly; and electronic health records (EHR) are connected to other sources of data to provide evidence-based support for the generation of research hypotheses and clinical decision-making.

- To that end, Komen — with a grant from The Robertson Foundation — convened the first Big Data for Breast Cancer symposium in New York, bringing 80 health, technology and patient advocacy leaders together to explore Big Data’s potential in breast cancer.

- Komen leadership and Scientific Advisory Board recommended the following four key areas in which Komen is positioned to play a role in driving Big Data applications for oncology forward.

  - Convene additional, “deep dive” meetings with specific groups of stakeholders to discuss important information such as patient privacy laws and policies that support Big Data.
  - Develop educational materials to educate patients and the public about Big Data, why it’s important and how it would be beneficial to them to participate in this initiative.
  - Recruit and cross-train individuals in the fields of informatics and breast cancer biology/oncology.
  - Provide research funding to encourage collaboration between the informatics and oncology research communities and find ways to integrate data across multiple sources to drive improvements in both research and clinical care.
Philanthropy and Stewardship

The generosity of our donors, partners, Race participants, 3-Day walkers and crew and those who have explored innovative ways to help us raise money and garner support has allowed us to continue striving to save lives and further our mission of ending breast cancer forever. Together, we’re fueling breakthrough research and providing access to screening and treatment for millions across the globe.

David M. Rubenstein

Through generous funding of donors like David Rubenstein’s $250,000 gift in 2016, grants are awarded to nonprofit organizations to provide breast health services, treatment assistance and patient support services to low-income, minority and under- or uninsured women. Services and assistance provided by local programs are contributing to the reduction in breast cancer incidence, mortality, and the number of late-stage diagnoses in the National Capital Region. As a Global Ambassador for Susan G. Komen and Founding Chair of Honoring the Promise, Rubenstein has played an integral role in bringing to the forefront the need for high-quality breast cancer care for all.

The National Capital Region, which includes Washington, D.C. and surrounding areas in Maryland and Virginia, has the highest incidence and mortality rates for breast cancer in the United States. Susan G. Komen’s National Capital Region Community Grants are awarded annually and provide funding for high-impact breast cancer programs that work to reduce rates of late-stage diagnosis and breast cancer mortality with an emphasis on eliminating breast cancer disparities.

The Milburn Foundation

Since 2012, The Milburn Foundation has supported Komen with an annual gift of $50,000, used for funding triple negative breast cancer (TNBC) research led by Komen Scholar Dr. Jennifer Pietenpol. In March 2016, Milburn launched a new partnership alongside Komen titled “The Milburn Foundation Matching Gifts Campaign.” Throughout the month of March, Milburn agreed to match dollar-for-dollar — up to $50,000 — all email, direct mail, website, and social media donations made to Komen. The matching program was a success, raising a total of $409,749 and allowing donors the opportunity to select their preferred area of mission funding.

Zumba® Global Research Grant for Breast Cancer Prevention

The Zumba Global Research Grant for Breast Cancer Prevention is focused on evaluating SDG, a component of flaxseed, for the prevention of breast cancer. Evidence shows that SDG blocks the estrogen receptors on cells within breast tissue, starving them of full-strength estrogen, preventing cell damage and possibly stopping tumor growth. This outcome would be most effective in younger, premenopausal women and is particularly exciting for areas across the globe where women are less likely to have access to state-of-the-art screening and treatment facilities.

In FY16, Zumba® launched its sixth annual Party in Pink™ campaign. Party in Pink encourages Zumba® instructors to host a Zumbathon®, and invite breast cancer survivors and everyone else to dance in support of the cause. From August 17 through October 31, 100 percent of all individual donations received at Party in Pink™ events was donated to Komen in support of the Zumba® Global Research Grant for Breast Cancer Prevention. Since the program’s inception in 2013, Zumba has hosted approximately 500 events per year, in addition to providing a guaranteed annual minimum $3 million donation through 2017 to support the grant.

Our stewards and ambassadors are part of a community of supporters who share our vision —

a world without breast cancer.
Susan G. Komen Race for the Cure®

With more than 150 Race for the Cure events across nine countries, the Susan G. Komen Race for the Cure® series involves more than 1 million participants annually and has raised more than $2 billion since inception, while educating the public and honoring those affected by the disease. In FY16 the Race for the Cure® Series raised nearly $75 million, with up to 75 percent of funds supporting breast cancer education, screening and treatment programs in the local host community and the remaining 25 percent supporting national research.

Susan G. Komen 3-Day®. 3 Days. 60 Miles. To end breast cancer forever.

The Komen 3-Day® is a 60-mile walk over the course of three days. In 2015, 13,000 walkers raised nearly $20 million for cutting-edge research and lifesaving treatment programs. Since its inception in 2003, the more than 500,000 walkers and crew have raised $800 million. That equates to more than 32.3 billion steps in the fight to end breast cancer.

Male Breast Cancer: Rare but Real. Meet the Gillas.

After husband and father Lee Giller was diagnosed with breast cancer in 2005, the family decided to walk in the Boston 3-Day. Their team, “Breast Man Walking,” raises awareness for male breast cancer and has participated in over 18 3-Day walks since 2006. The 3-Day brought together family and friends in support of Lee when he needed them the most, but there is still more research to be done, more money to be raised, and more steps to walk in the fight against breast cancer.
Consolidated Statement of Financial Position

<table>
<thead>
<tr>
<th></th>
<th>As of March 31,</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
<td>2016</td>
</tr>
<tr>
<td><strong>Assets:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>154,493,674</td>
<td>129,199,058</td>
</tr>
<tr>
<td>Investments</td>
<td>150,955,855</td>
<td>172,987,203</td>
</tr>
<tr>
<td>Receivables</td>
<td>39,969,851</td>
<td>40,873,951</td>
</tr>
<tr>
<td>Prepaid expense and other assets</td>
<td>3,867,213</td>
<td>2,508,658</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>2,798,585</td>
<td>2,340,772</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td>352,085,158</td>
<td>347,909,642</td>
</tr>
<tr>
<td><strong>Liabilities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable, accrued expenses, and other payables</td>
<td>7,806,906</td>
<td>7,928,800</td>
</tr>
<tr>
<td>Deferred revenue and rent</td>
<td>2,560,573</td>
<td>2,373,457</td>
</tr>
<tr>
<td>Grants payable, net</td>
<td>164,476,949</td>
<td>139,164,800</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td>174,844,428</td>
<td>149,467,057</td>
</tr>
<tr>
<td><strong>Net Assets:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted - undesignated</td>
<td>119,868,140</td>
<td>118,171,612</td>
</tr>
<tr>
<td>Unrestricted - board designated</td>
<td>1,000,000</td>
<td>1,000,000</td>
</tr>
<tr>
<td><strong>Total unrestricted</strong></td>
<td>120,868,140</td>
<td>119,171,612</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>56,047,590</td>
<td>78,945,973</td>
</tr>
<tr>
<td>Permanently restricted</td>
<td>325,000</td>
<td>325,000</td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td>177,240,730</td>
<td>198,442,585</td>
</tr>
<tr>
<td><strong>Total Liabilities and Net Assets</strong></td>
<td>352,085,158</td>
<td>347,909,642</td>
</tr>
</tbody>
</table>

Consolidated Statement of Activities

<table>
<thead>
<tr>
<th></th>
<th>Fiscal Year Ended March 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
</tr>
<tr>
<td><strong>Public support and revenue:</strong></td>
<td></td>
</tr>
<tr>
<td>Contributions</td>
<td>117,880,939</td>
</tr>
<tr>
<td>Komen Race for the Cure &amp; Breast Cancer 3 Day</td>
<td>149,489,011</td>
</tr>
<tr>
<td>Less: Direct benefit to donors and sponsors</td>
<td>(25,130,890)</td>
</tr>
<tr>
<td><strong>Net Public Support</strong></td>
<td>242,239,060</td>
</tr>
<tr>
<td><strong>Revenue:</strong></td>
<td></td>
</tr>
<tr>
<td>Investment Income/(Loss)</td>
<td>7,521,315</td>
</tr>
<tr>
<td>Other Income</td>
<td>515,987</td>
</tr>
<tr>
<td><strong>Total Revenue</strong></td>
<td>8,037,292</td>
</tr>
<tr>
<td><strong>Total Net Public Support and Revenue:</strong></td>
<td>250,276,362</td>
</tr>
<tr>
<td><strong>Expenses:</strong></td>
<td></td>
</tr>
<tr>
<td>Program Services</td>
<td>216,147,708</td>
</tr>
<tr>
<td>Management and General</td>
<td>20,719,400</td>
</tr>
<tr>
<td>Fundraising</td>
<td>31,992,548</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td>268,859,656</td>
</tr>
<tr>
<td>Change in net assets</td>
<td>(18,583,294)</td>
</tr>
<tr>
<td>Net Assets, beginning of year</td>
<td>177,240,730</td>
</tr>
<tr>
<td><strong>Net assets end of year</strong></td>
<td>177,240,730</td>
</tr>
</tbody>
</table>

Mission Advisors

Komen’s Mission Advisors are the best and brightest breast cancer researchers, clinicians, advocates and other experts who help guide and implement our mission programs.

Thanks to their efforts, we’re driving discovery, affecting change and accelerating progress in the fight against breast cancer.

Scientific Advisory Board

The Scientific Advisory Board (SAB) provides strategic guidance and direction for our research and scientific programs, and plays a key role in guiding and prioritizing Komen’s global research investment.

The SAB is led by Komen’s chief scientific advisors.

- George Sledge, Jr., M.D., Chief Scientific Advisor
  Stanford University School of Medicine
  Stanford, CA

- Eric Winer, M.D., Chief Scientific Advisor
  Dana-Farber Cancer Institute
  Boston, MA

- Carlos Arteaga, M.D.
  Vanderbilt-Ingram Cancer Center
  Nashville, TN

- Myles Brown, M.D.
  Dana-Farber Cancer Institute
  Boston, MA

- Powel Brown, M.D., Ph.D.
  The University of Texas MD Anderson Cancer Center
  Houston, TX

- Karen Gelmon, M.D., F.R.C.P.C.
  British Columbia Cancer Agency
  Vancouver, Canada

- Cheryl Jernigan, C.P.A., F.A.C.H.E.
  Advocate in Science
  Komen Greater Kansas City Affiliate
  Kansas City, MO

- Amelie Ramirez, Dr. P.H.
  The University of Texas Health Science Center at San Antonio
  San Antonio, TX
Komen Scholars —
an advisory group of 62 distinguished leaders in breast cancer research and advocacy.

Representing more than 35 institutions in six countries, their expertise spans everything from clinical research, laboratory research, pathology, prevention, radiation oncology, surgery and other disciplines and specialties. They contribute to our programs, activities and events in many ways — most notably by leading and participating as reviewers in our scientific grants review process — and act as our ambassadors in communities around the U.S. and the world.

Several of the Komen Scholars are Advocates in Science who ensure that the unique perspectives of those affected by breast cancer are fully integrated into decisions at every step of the research process.

Lisa Carey, M.D.
UNC Lineberger Comprehensive Cancer Center – University of North Carolina School of Medicine
Chapel Hill, NC

E. Claire Dees, M.D., Sc.M.
UNC Lineberger Comprehensive Cancer Center – University of North Carolina School of Medicine
Chapel Hill, NC

Angelo Di Leo, M.D., Ph.D.
Hospital of Prato, Instituto Toscano Tumori
Prato, Italy

Mary L. “Nora” Disis, M.D.
Fred Hutchinson Cancer Research Center – University of Washington School of Medicine
Seattle, WA

Patricia Ganz, M.D.
The University of California, Los Angeles School of Medicine
Los Angeles, CA

Mary-Claire King, Ph.D.
University of Washington School of Medicine
Seattle, WA

Bella Kaufman, M.D.
Sheba Medical Center
Tel Hashomer, Israel

V. Craig Jordan, OBE, Ph.D., D.Sc., F.Med.Sci.
The University of Texas MD Anderson Cancer Center
Houston, TX

Harkirshna Nakshatri, B.V.Sc., Ph.D.
Indiana University School of Medicine
Indianapolis, IN

continued

Adrian Lee, Ph.D.
University of Pittsburgh Cancer Institute
Pittsburgh, PA

David Livingston, M.D.
Dana-Farber Cancer Institute
Boston, MA

David Mankoff, M.D., Ph.D.
Perelman School of Medicine - University of Pennsylvania
Philadelphia, PA

Nadia Mercier-Bernstat, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX

Kathy Miller, M.D.
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, IN

Gordon Mills, M.D., Ph.D.
The University of Texas MD Anderson Cancer Center
Houston, TX

Ian Krop, M.D., Ph.D.
Dana-Farber Cancer Institute
Boston, MA
Olufunmilayo Olopade, M.D.
University of Chicago Medical Center
Chicago, IL

Bert O’Malley, M.D.
Baylor College of Medicine
Houston, TX

Ramon Parsons, M.D., Ph.D.
Icahn School of Medicine at Mount Sinai
New York, NY

Ann Partridge, M.D., M.P.H
Dana-Farber Cancer Institute
Boston, MA

Jennifer Pietenpol, Ph.D.
Vanderbilt-Ingram Cancer Center
Nashville, TN

Jeffrey Rosen, Ph.D.
Baylor College of Medicine
Houston, TX

Geoffrey Wahl, Ph.D.
The Salk Institute for Biological Studies
La Jolla, CA

Danny Welch, Ph.D.
University of Kansas Cancer Center
Kansas City, KS

Julia White, M.D.
Stephanie Spelman Comprehensive Breast Center - The Ohio State University Medical School
Columbus, OH

Antonio Wolff, M.D.
Sidney Kimmel Comprehensive Cancer Center - John Hopkins University School of Medicine
Baltimore, MD

Kimberly Wright
Advocate in Science
Komen Maryland Affiliate
Reistertown, MD

Susan G. Komen Board of Directors

Linda Custard, Chair
Nancy Brinker, Founder
Connie O’Neill, Treasurer
Jane Abraham
Kaye Ceille
Alan Feld
Janet Dunn Franz
Dan Glennon
Melissa Maxfield
Dr. Olufunmilayo “Funmi” Olopade, M.D., F.A.C.P.
Meghan Shannon
Linda Wilkins

Susan G. Komen Officers

Judith A. Salerno, M.D., M.S., President and CEO
Ellen Willmott, General Counsel and Secretary
Bob Green, Chief Financial Officer
Christina Alford, SVP, Development
Carrie Walsh, SVP, Marketing
Victoria Wolodzko, VP, Research and Community Health
Miguel Perez, VP, Affiliate Network
Leslie Lurie, Deputy Counsel and Assistant Secretary
Eric Montgomery, VP, Information Technology

Komen Scholars continued

Bryan Schneider, M.D.
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, IN

Christos Sotiriou, M.D., Ph.D.
Jules Bordet Institute
Brussels, Belgium

Patricia Spears
Advocate in Science
Komen NC Triangle to the Coast Affiliate
Raleigh, NC

Neil Spector, M.D.
Duke University School of Medicine
Durham, NC

Vered Stearns, M.D.
Sidney Kimmel Comprehensive Cancer Center - John Hopkins University School of Medicine
Baltimore, MD

W. Fraser Symmans, M.D.
The University of Texas MD Anderson Cancer Center
Houston, TX

Melinda Telli, M.D.
Stanford University School of Medicine
Stanford, CA

Geoffrey Wahl, Ph.D.
The Salk Institute for Biological Studies
La Jolla, CA

Danny Welch, Ph.D.
University of Kansas Cancer Center
Kansas City, KS

Julia White, M.D.
Stephanie Spelman Comprehensive Breast Center - The Ohio State University Medical School
Columbus, OH

Antonio Wolff, M.D.
Sidney Kimmel Comprehensive Cancer Center - John Hopkins University School of Medicine
Baltimore, MD

Kimberly Wright
Advocate in Science
Komen Maryland Affiliate
Reistertown, MD

Douglas Yee, M.D.
Masonic Cancer Center – University of Minnesota School of Medicine
Minneapolis, MN
We refuse to give up. **Ever.**